Abstract: The present invention relates to a method for treatment of sepsis in a subject comprising administering a pharmaceutical composition comprising an effective amount of allogeneic Natural Killer cells to said subject, and to methods for predicting a subject's susceptibility to such method of treatment.

Abstract: Provided in embodiments of the disclosure are a media processing method, device and system, and the computer-readable storage medium. The media processing method includes: in a media file, describing position information and/or position change information of a user; and processing the media file to determine a video to be played. As such, by describing position information and/or position change information of a user in the media file, the video frame can be adjusted in real time according to the position of the user, thereby improving the quality of viewing by the user and improving user experience.

Abstract: A silicon-based anode material for secondary batteries, a preparation method thereof and a secondary battery are provided. The silicon-based anode material includes: an inner core including an Si particle and silicon oxide SiOx1, where 0<x1<2, a first shell layer including a compound of the general formula MySiOz (0<y?4, 0<z?5, and z?x1) and a C particle, wherein the first shell layer covers the inner core, and the contents of M and C in the first shell layer gradually increase from a side thereof close to the inner core to another side thereof far away from the inner core; and a second shell layer including a carbon film layer or a composite film layer formed by a carbon film layer and a conductive additive, the second shell layer covers the first shell layer. The first charge-discharge cycle capability of the silicon-based anode material is improved, and the manufacturing cost is reduced.

Abstract: The disclosure provides a novel method for treating genetic disorders where a peptide sequence targets proteins produced via gene therapy into exosomes. These protein-loaded exosomes can enter into non-transduced cells and correct pathology. Also, gene therapy compositions, protein replacement therapy composition, pharmaceutical compositions, methods of treatment, and uses of the gene therapy compositions and the recombinant proteins are also disclosed. The method can also be used to improve in vitro recombinant protein yield.

Abstract: Physiologically-tailored tissue organoids are disclosed for monitoring and treating diseases and improving an individual's health.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: A flapping-wing aerial robot formation control method includes: determining a trailing vortex generation mechanism, an energy saving principle and a trailing vortex attenuation mechanism of the formation flight of a group of wild geese in accordance with the pattern of the formation flight of the group of wild geese; determining the formation flight of a group of flapping-wing aerial robots and a formation switching solution in accordance with the trailing vortex generation mechanism, energy saving principle and trailing vortex attenuation mechanism of the formation flight of the group of wild geese in conjunction with the flapping characteristic of a flapping-wing aerial robot from the perspective of energy consumption equalization and energy saving; and carrying out formation keeping control and formation reconfiguration control in accordance with the formation flight of the group of flapping-wing aerial robots and the formation switching solution by controlling positions of the group of flapping-wing aeria

Abstract: A flapping-wing aerial robot formation control method includes: determining a trailing vortex generation mechanism, an energy saving principle and a trailing vortex attenuation mechanism of the formation flight of a group of wild geese in accordance with the pattern of the formation flight of the group of wild geese; determining the formation flight of a group of flapping-wing aerial robots and a formation switching solution in accordance with the trailing vortex generation mechanism, energy saving principle and trailing vortex attenuation mechanism of the formation flight of the group of wild geese in conjunction with the flapping characteristic of a flapping-wing aerial robot from the perspective of energy consumption equalization and energy saving; and carrying out formation keeping control and formation reconfiguration control in accordance with the formation flight of the group of flapping-wing aerial robots and the formation switching solution by controlling positions of the group of flapping-wing aeria

Abstract: Methods and compositions for preventing or inhibiting the formation of scars are disclosed. The methods and compositions include a TGF-? inhibitor provided in a delayed release composition.

Abstract: Compositions and methods are provided concerning a lactate-responsive drug release system. In some embodiments, there are methods and compositions for treating cancer that take advantage of the tumor environment to deliver therapeutic agents to the tumor while reducing problems associated with circulating drugs in the patients body.

Abstract: Embodiments of the present application provide a method, apparatus, and electronic device for eliminating distortion of a distorted image. Side information components of a distorted image are generated. The distorted image is resulted from image processing on an original image. Side information components represent distortion features of the distorted image with respect to original image. Distorted image color components of the distorted image and the side information components are input into a pre-established convolutional neural network model for convolution filtering to obtain distortion-eliminated image color components. The convolutional neural network model is obtained through training based on a preset training set. The training set comprises original sample images, distorted image color components of multiple distorted images corresponding to each of the original sample images, and side information components of each of the distorted images.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: Embodiments of the present application provide a method, apparatus, and electronic device for eliminating distortion of a distorted image. Side information components of a distorted image are generated. The distorted image is resulted from image processing on an original image. Side information components represent distortion features of the distorted image with respect to original image. Distorted image color components of the distorted image and the side information components are input into a pre-established convolutional neural network model for convolution filtering to obtain distortion-eliminated image color components. The convolutional neural network model is obtained through training based on a preset training set. The training set comprises original sample images, distorted image color components of multiple distorted images corresponding to each of the original sample images, and side information components of each of the distorted images.

Abstract: Provided herein are macrophages engineered for treating fibrosis and ameliorating the effects of fibrotic lesions in various organs and tissues. Certain embodiments are directed to genetically-engineered macrophages capable of treating fibrosis or reducing fibrotic lesions. In certain aspects macrophages can be genetically-engineered to (1) target extracelluar matrix (ECM) or components thereof, (2) enhance degradation of ECM, or (3) target ECM and enhance degradation of ECM. Further provided is a cellular therapy product comprising a genetically-engineered macrophage comprising at least one of a recombinant targeting protein and a recombinant catalytic enzyme. Further provided is a method of treating an individual for fibrosis comprising administering the cellular therapy product.

Abstract: Provided are methods of treating a patient diagnosed with Fabry disease and methods of enhancing ?-galactosidase A in a patient diagnosed with or suspected of having Fabry disease. Certain methods comprise administering to a patient a therapeutically effective dose of a pharmacological chaperone for ?-galactosidase A, wherein the patient has a mutation in the nucleic acid sequence encoding ?-galactosidase A. Also described are uses of pharmacological chaperones for the treatment of Fabry disease and compositions for use in the treatment of Fabry disease.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Abstract: A bit rate control method device obtains a bit rate control mode and coding control parameters of a current short period in a long period, determines a frame-level coding parameter of the current short period, and transmits the frame-level coding parameter to an encoder. Second bit stream information is obtained and statistical analysis is performed which includes complexity information of the current video frame, the number of the encoded bits in the current short period, and coding quality information of the current short period, so as to encode a video frame of the next, adjacent short period by calculating a frame-level coding parameter of the next, adjacent short period. By the present solution, the storage space is allocated reasonably under the condition that the image satisfies a certain quality.

Abstract: When performing an inter predictive encoding on any image frame x is required, a reference image frame is determined for image x; image x is a P-frame image or a B-frame image; for each reference image frame, following processes are respectively performed: whether resolution of a reference image frame is the same as resolution of image x is determined; if resolution of the reference image frame is different from resolution of image x, resolution of reference image frame is adjusted to be the same as resolution of image x; if resolution of each reference image frame is the same as resolution of image x, inter predictive encoding is performed on image x based on each reference image frame.

Abstract: The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining ?-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of ?-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.